Florida Biologix, an Alachua, FL-based contract development and manufacturing organization (CDMO) focused on complex biological products, received financial backing from Ampersand Capital Partners.
The investment will be used to further expand the company’s manufacturing capabilities in the areas of gene and cell therapies.
Established in 2006 as a component of the UF Center of Excellence for Regenerative Health Biotechnology, Florida Biologix has spun-off from the University of Florida (UF) to offer a wide range of cGMP-compliant biopharmaceutical development, manufacturing and analytical testing services. As a Contract Development and Manufacturing Organization (CDMO), the company manufactures complex biological drug products for pre-clinical studies, early human clinical trials, and late stage and commercial sale.
Florida Biologix will continue to operate out of its existing Progress Park facility, and will also lease UF facilities on Innovation Drive in Alachua, FL.
Most of the more than 100 UF Florida Biologix employees will continue with the business, including founding director Richard Snyder and all of the senior scientific team. In connection with Ampersand’s investment, Tim Martin was recruited to serve as CEO of the company.
FinSMEs
19/11/2015